93 related articles for article (PubMed ID: 38455663)
1. Leptin Promotes Vasculogenic Mimicry in Breast Cancer Cells by Regulating Aquaporin-1.
Han DS; Lee EO
Int J Mol Sci; 2024 May; 25(10):. PubMed ID: 38791252
[TBL] [Abstract][Full Text] [Related]
2. Cyclopeptide moroidin inhibits vasculogenic mimicry formed by glioblastoma cells
Min P; Li Y; Wang C; Fan J; Liu S; Chen X; Tang Y; Han F; Zhang A; Feng L
J Biomed Res; 2024 May; ():1-11. PubMed ID: 38807414
[TBL] [Abstract][Full Text] [Related]
3. COL5A2 drives regorafenib resistance-induced metastatic phenotype via reducing LIFR expression in hepatocellular carcinoma.
Zhang S; Xue X; Chen F; Yang Y; Zhang N; Chen Y; Wu W; Wang J; Zheng N
Acta Biochim Biophys Sin (Shanghai); 2024 May; ():. PubMed ID: 38818582
[TBL] [Abstract][Full Text] [Related]
4. The in vitro dynamics of pseudo-vascular network formation.
Oraiopoulou ME; Couturier DL; Bunce EV; Cannell IG; Sweeney PW; Naylor H; Golinska M; Hannon GJ; Sakkalis V; Bohndiek SE
Br J Cancer; 2024 Jun; ():. PubMed ID: 38902534
[TBL] [Abstract][Full Text] [Related]
5. Molecular mechanisms of Thrombospondin-2 modulates tumor vasculogenic mimicry by PI3K/AKT/mTOR signaling pathway.
Huang J; Wang C; Hou Y; Tian Y; Li Y; Zhang H; Zhang L; Li W
Biomed Pharmacother; 2023 Nov; 167():115455. PubMed ID: 37696083
[TBL] [Abstract][Full Text] [Related]
6. Vasculogenic mimicry: current status and future prospects.
Zhang S; Zhang D; Sun B
Cancer Lett; 2007 Sep; 254(2):157-64. PubMed ID: 17306454
[TBL] [Abstract][Full Text] [Related]
7. Doxazosin inhibits vasculogenic mimicry in human non‑small cell lung cancer through inhibition of the VEGF‑A/VE‑cadherin/mTOR/MMP pathway.
Hsu JL; Leu WJ; Hsu LC; Hsieh CH; Guh JH
Oncol Lett; 2024 Apr; 27(4):170. PubMed ID: 38455663
[TBL] [Abstract][Full Text] [Related]
8. Tumor-expressed B7-H3 promotes vasculogenic mimicry formation rather than angiogenesis in non-small cell lung cancer.
Fan X; Huang J; Hu B; Zhou J; Chen L
J Cancer Res Clin Oncol; 2023 Sep; 149(11):8729-8741. PubMed ID: 37129607
[TBL] [Abstract][Full Text] [Related]
9. Ginsenoside Rg3 inhibition of vasculogenic mimicry in pancreatic cancer through downregulation of VE‑cadherin/EphA2/MMP9/MMP2 expression.
Guo JQ; Zheng QH; Chen H; Chen L; Xu JB; Chen MY; Lu D; Wang ZH; Tong HF; Lin S
Int J Oncol; 2014 Sep; 45(3):1065-72. PubMed ID: 24938458
[TBL] [Abstract][Full Text] [Related]
10. Serum promotes vasculogenic mimicry through the EphA2/VE-cadherin/AKT pathway in PC-3 human prostate cancer cells.
Yeo C; Lee HJ; Lee EO
Life Sci; 2019 Mar; 221():267-273. PubMed ID: 30797819
[TBL] [Abstract][Full Text] [Related]
11. Contribution of the PI3K/MMPs/Ln-5γ2 and EphA2/FAK/Paxillin signaling pathways to tumor growth and vasculogenic mimicry of gallbladder carcinomas.
Lu XS; Sun W; Ge CY; Zhang WZ; Fan YZ
Int J Oncol; 2013 Jun; 42(6):2103-15. PubMed ID: 23588386
[TBL] [Abstract][Full Text] [Related]
12. Celastrol Suppresses Glioma Vasculogenic Mimicry Formation and Angiogenesis by Blocking the PI3K/Akt/mTOR Signaling Pathway.
Zhu Y; Liu X; Zhao P; Zhao H; Gao W; Wang L
Front Pharmacol; 2020; 11():25. PubMed ID: 32116702
[TBL] [Abstract][Full Text] [Related]
13. αV-Integrin-Dependent Inhibition of Glioblastoma Cell Migration, Invasion and Vasculogenic Mimicry by the uPAcyclin Decapeptide.
Franco P; Camerino I; Merlino F; D'Angelo M; Cimmino A; Carotenuto A; Colucci-D'Amato L; Stoppelli MP
Cancers (Basel); 2023 Sep; 15(19):. PubMed ID: 37835469
[TBL] [Abstract][Full Text] [Related]
14. VE-Cadherin in Cancer-Associated Angiogenesis: A Deceptive Strategy of Blood Vessel Formation.
Delgado-Bellido D; Oliver FJ; Vargas Padilla MV; Lobo-Selma L; Chacón-Barrado A; Díaz-Martin J; de Álava E
Int J Mol Sci; 2023 May; 24(11):. PubMed ID: 37298296
[TBL] [Abstract][Full Text] [Related]
15. Emerging Targeted Therapies in Advanced Non-Small-Cell Lung Cancer.
Li S; de Camargo Correia GS; Wang J; Manochakian R; Zhao Y; Lou Y
Cancers (Basel); 2023 May; 15(11):. PubMed ID: 37296863
[TBL] [Abstract][Full Text] [Related]
16.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
17.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
18.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
19.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
20.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Next] [New Search]
